Technology | Thrombectomy Devices | July 25, 2019

Penumbra Launches Jet 7 Reperfusion Catheter With Xtra Flex Technology in U.S.

Catheter is used with Penumbra Engine in fully integrated Penumbra System for aspiration-based mechanical thrombectomy

Penumbra Launches Jet 7 Reperfusion Catheter With Xtra Flex Technology in U.S.

July 25, 2019 — Penumbra announced U.S. commercial availability of the Penumbra System’s most advanced technology, the Penumbra Jet 7 Reperfusion Catheter with Xtra Flex technology, at the Society of NeuroInterventional Surgery (SNIS) 16th Annual Meeting, July 22-25 in Miami. Penumbra Jet 7 with Xtra Flex technology is used with the Penumbra Engine in the fully integrated Penumbra System – an aspiration-based mechanical thrombectomy system that enables physicians to extract thrombus in acute ischemic stroke patients.

The Penumbra System is a fully integrated system designed specifically for mechanical thrombectomy by aspiration that first received 510(k) clearance by the U.S. Food & Drug Administration (FDA) in December 2007. It enables physicians to use aspiration, which acts like a minimally invasive “vacuum” inside the artery to remove stroke-causing blood clots from the brain safely and effectively. It is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusion.

The Penumbra Jet 7 Reperfusion Catheter with Xtra Flex technology is the latest advancement in the Penumbra System Jet – Engine family of products, which was launched last September.  As the eighth-generation reperfusion catheter for proximal large vessel occlusions, the catheter is designed for advanced trackability and navigation, and maintains the large 0.072-inch lumen.  Penumbra Jet 7 with Xtra Flex technology together with the power of the Penumbra Engine are designed to maximize thrombus removal force.

Initial clinical experience with the new technology was shared in the Industry Technology Luncheon Symposium by Donald F. Frei, M.D., director of neuro-interventional surgery, Swedish Medical Center, Englewood, Colo. 

For more information: www.penumbrainc.com


Related Content

Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 22, 2025 — Heartflow, Inc. has introduced Heartflow PCI Navigator, the newest addition to the Heartflow One ...

Home October 23, 2025
Home
News | Cath Lab

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to ...

Home October 16, 2025
Home
News | Cath Lab

Oct. 7, 2025 — Medtronic has announced the full distribution of the Neuroguard IEP System (Neuroguard) after a ...

Home October 07, 2025
Home
News | Cath Lab

Sept. 22, 2025 — Nicklaus Children's Heart Institute in Miami, Florida, is now offering bedside transcatheter patent ...

Home September 23, 2025
Home
Subscribe Now